Related Experiment Video
Updated: May 13, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
[Antithrombotic management in atrial fibrillation]
Laurent Fauchier1, Sophie Taillandier, Nicolas Clementy
1Service de cardiologie, Centre hospitalier universitaire Trousseau, 37044 Tours, France. Ifau@med.univ-tours.fr
La Revue Du Praticien
|March 22, 2013
Summary
New oral anticoagulants offer safer stroke prevention for atrial fibrillation (AF) patients compared to older treatments. Risk scores like CHA2DS2-Vasc and HAS-BLED help guide appropriate oral anticoagulation therapy decisions.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Atrial fibrillation (AF) necessitates stroke prevention strategies.
- Vitamin K antagonists (VKA) have limitations in anticoagulation therapy.
- Newer oral anticoagulants (NOACs) present an alternative.
Purpose:
- To review the role of oral anticoagulation in stroke prevention for AF patients.
- To discuss risk stratification scores (CHA2DS2-Vasc and HAS-BLED).
- To compare NOACs with VKAs.
Summary:
- The CHA2DS2-Vasc score identifies low-risk AF patients (score 0) who may not need antithrombotic therapy.
- Patients with CHA2DS2-Vasc score ≥1 benefit from oral anticoagulation consideration.
- The HAS-BLED score assesses bleeding risk (≥3 indicates high risk), prompting caution and review of modifiable factors.
- NOACs like dabigatran, rivaroxaban, and apixaban are effective and safe alternatives to VKAs in non-valvular AF.
- NOACs offer easier use, predictable effects, fewer interactions, and reduced intracranial bleeding risk compared to VKAs.
- NOACs are contraindicated in patients with kidney disease.
Impact:
- Improved patient selection for oral anticoagulation therapy.
- Enhanced management of bleeding risk in AF patients.
- Increased utilization of safer and more effective anticoagulation treatments for stroke prevention in AF.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:26Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:25Dysrhythmias VI: Management of Dysrhythmias
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...